title: A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa.
abstract: BACKGROUND
  Colistin is used as last treatment option for pneumonia associated with multidrug-resistant (MDR) Pseudomonas spp.. Literature about the best administration mode (inhalation versus parenteral treatment) is lacking.
  
  
  METHODS
  A retrospective study of 20 intensive care patients with a pneumonia associated with MDR P. aeruginosa receiving colistin sulphomethate sodium (Colistineb®) between 2007 and 2009 was performed. A strain was considered multidrug-resistant if it was resistant to at least 6 of the following antibiotics: piperacillin-tazobactam, ceftazidime, cefepime, meropenem, aztreonam, ciprofloxacin, and amikacin. The administration mode, predicted mortality based on the SAPS3 score, SOFA score at onset of the colistin treatment, clinical and microbiological response, and mortality during the episode of the infection were analysed. The non parametric Kruskal-Wallis and Fisher's Exact test were used for statistical analysis of respectively the predicted mortality/SOFA score and mortality rate.
  
  
  RESULTS
  Six patients received colistin by inhalation only, 5 were treated only parenterally, and 9 by a combination of both administration modes. All patients received concomitant beta-lactam therapy. The mean predicted mortalities were respectively 72%, 68%, and 69% (p = 0.91). SOFA scores at the onset of the treatment were also comparable (p = 0.87). Clinical response was favorable in all patients receiving colistin by inhalation (6/6) and in 40% (2/5) of the patients receiving colistin parenterally (p = 0.06). In the patients with colistin administered both via inhalation and parenterally, clinical response was favorable in 78% of the patients (7/9) (p = 0.27 as compared to the treatment group receiving colistin only parenterally). When all patients with inhalation therapy were compared to the group without inhalation therapy, a favorable clinical response was present in respectively 87% and 40% (p = 0.06). In none of the patients, the Pseudomonas spp. was eradicated from the follow-up cultures.All patients in the parenterally treated group died. None of the patients receiving colistin by inhalation, and 3 of 9 patients of the combination group eventually died (p = 0.002 and p = 0.03 respectively as compared to the group receiving colistin only parenterally).
  
  
  CONCLUSIONS
  Aerosolized colistin could be beneficial as adjunctive treatment for the management of pneumonia due to MDR P. aeruginosa.
authors.affiliation: Laboratory of Medical Microbiology, Antwerp University Hospital, Edegem, Belgium. reinoutnaesens@hotmail.com
authors.forename: Reinout
authors.initials: R
authors.lastname: Naesens
authors.forename: Erika
authors.initials: E
authors.lastname: Vlieghe
authors.forename: Walter
authors.initials: W
authors.lastname: Verbrugghe
authors.forename: Philippe
authors.initials: P
authors.lastname: Jorens
authors.forename: Margareta
authors.initials: M
authors.lastname: Ieven
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003091:Colistin / Q000008:administration & dosage*; D003428:Cross Infection / Q000188:drug therapy*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D003091:Colistin
references.citation: Clin Infect Dis. 2009 Jun 15;48(12):1724-8
references.pmid: 19438394
references.citation: Intensive Care Med. 2008 Oct;34(10):1873-7
references.pmid: 18592214
references.citation: Respir Med. 2008 Mar;102(3):407-12
references.pmid: 18060758
references.citation: Crit Care. 2003 Oct;7(5):R78-83
references.pmid: 12974973
references.citation: Diagn Microbiol Infect Dis. 2007 Jun;58(2):235-40
references.pmid: 17350201
references.citation: J Med Microbiol. 2006 Dec;55(Pt 12):1619-1629
references.pmid: 17108263
references.citation: Clin Microbiol Infect. 2006 Jan;12(1):56-62
references.pmid: 16460547
references.citation: Clin Microbiol Infect. 2010 Aug;16(8):1230-6
references.pmid: 19732088
references.citation: J Antimicrob Chemother. 2009 Aug;64(2):229-38
references.pmid: 19520717
references.citation: J Antimicrob Chemother. 2006 Feb;57(2):306-11
references.pmid: 16396919
references.citation: Intensive Care Med. 2005 Aug;31(8):1058-65
references.pmid: 15983759
references.citation: Crit Care. 2005 Feb;9(1):R53-9
references.pmid: 15693967
references.citation: BMC Infect Dis. 2005 Jan 10;5:1
references.pmid: 15642116
references.citation: Am J Respir Crit Care Med. 2000 Jul;162(1):328-30
references.pmid: 10903263
references.citation: Lancet Infect Dis. 2006 Sep;6(9):589-601
references.pmid: 16931410
references.citation: Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
references.pmid: 15699079
references.citation: Infection. 2009 Oct;37(5):461-5
references.pmid: 19499183
references.citation: Am J Infect Control. 1988 Jun;16(3):128-40
references.pmid: 2841893
references.citation: Pharmacotherapy. 2009 Sep;29(9):1054-60
references.pmid: 19698010
references.citation: Intensive Care Med. 1996 Jul;22(7):707-10
references.pmid: 8844239
references.citation: Respir Med. 2009 May;103(5):707-13
references.pmid: 19118994